金楊股份(301210.SZ):2023年公司開發客户較多,包括新能安、海辰、楚能、中科海鈉、遠景、正力等業內知名客户
格隆匯2月2日丨金楊股份(301210.SZ)於2024年1月31日接受投資者調研,就“Q4和明年是否有新客户開拓及預期?”,公司回覆稱,公司客户大部分都是長期合作客户,如橫店東磁、億緯鋰能、力神電池、比克電池和C公司等;2023年公司開發客户較多,包括新能安、海辰、楚能、中科海鈉、遠景、正力等業內知名客户,部分新客户2024年下半年會有一定的收入體現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.